Once considered a “junk genome,” MicroRNA may prove to be instrumental in the difficult task of diagnosing mesothelioma, said Harvey Pass, M.D., of NYU Langone Medical Center and Cancer Center, speaking at the 4th Annual Emerging Trends in Asbestos Litigation Conference on April 8 in Chicago, produced by HB Litigation Conferences. Dr. Pass explained how research has shown that MicroRNA testing may also be instrumental in early detection of mesothelioma. Click below to hear what Dr. Pass had to say.